Physician profile
Ned Devasia
NPI 1255435376
$2,444.24
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $480 · 2021: $734 · 2022: $529 · 2023: $219 · 2024: $18.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,799.24 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $264.46 | 2019-2023 | Fasenra, Breztri |
| Vanda Pharmaceuticals INC. | $94.82 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $39.49 | 2021 | |
| Angiodynamics, INC. | $39.17 | 2021 | |
| Advanced Respiratory, INC | $32.06 | 2019-2021 | |
| Baxter Healthcare | $30.19 | 2023 | Hillrom - Life 2000 Ventilation System |
| Novo Nordisk INC | $24.97 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.40 | 2019 | |
| Lilly USA, LLC | $20.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.83 | 2019 | |
| Horizon Therapeutics Plc | $15.03 | 2020 | |
| Genzyme Corporation | $14.96 | 2020 | |
| Allergan, INC. | $14.19 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Devasia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.